Bruce Evan Johnson
Dana-Farber Cancer Institute · 1,012 works · 93,979 citations · h-index 123
Top works
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor Types
- EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
- Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
- Somatic mutations affect key pathways in lung adenocarcinoma
- Comprehensive genomic characterization of squamous cell lung cancers
- Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
- Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib
- Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer
- First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations
- Characterizing the cancer genome in lung adenocarcinoma
- Prophylactic Cranial Irradiation for Patients with Small-Cell Lung Cancer in Complete Remission
- TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer
- Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
- Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255
- Molecular Analysis of the Short Arm of Chromosome 3 in Small-Cell and Non-Small-Cell Carcinoma of the Lung
- ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines
- Twenty-Two Years of Phase III Trials for Patients With Advanced Non–Small-Cell Lung Cancer: Sobering Results
- Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, ‘Iressa’) on an expanded access study